German immunotherapeutics specialist BioNTech has inked a deal with RNA therapy specialist Genevant to guarantee further cooperation between the two on fighting rare diseases.
The deal will allow Genevant access to BioNTech's mRNA discovery platform, while the Mainz-based start-up will have access to the liquid nanoparticle delivery technology championed by the subsidiary of Roivant Sciences.
"BioNTech’s impressive molecular design expertise and Genevant’s leadership in RNA delivery are the ideal combination for developing cutting edge mRNA therapies"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze